Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23966692 | 0.84 | MEN1 (0.42) | ALDH1A1MAPK14MEN1KMT2ACNR2 | |
| SCHEMBL12602866 | 0.83 | MAPK14 (0.41) | ALDH1A1MAPK14MEN1KMT2ACNR2 | |
| SCHEMBL23966691 | 0.83 | ALDH1A1 (0.43) | ALDH1A1MAPK14MEN1KMT2ACNR2 | |
| SCHEMBL15684071 | 0.83 | ALDH1A1 (0.40) | ALDH1A1MAPK14MEN1KMT2ACNR2 | |
| SCHEMBL24033649 | 0.82 | MAPK14 (0.34) | MAPK14MEN1KMT2A | |
| SCHEMBL84872 | 0.81 | MEN1 (0.48) | ALDH1A1MAPK14MEN1KMT2ACNR2 | |
| SCHEMBL20852659 | 0.80 | ALDH1A1 (0.38) | ALDH1A1MAPK14MEN1KMT2ACNR2 | |
| SCHEMBL22968430 | 0.79 | ALDH1A1 (0.40) | ALDH1A1MAPK14MEN1KMT2ACNR2 | |
| SCHEMBL12650126 | 0.78 | HCAR2 (0.35) | MEN1KMT2ACNR2 | |
| SCHEMBL17755695 | 0.77 | ALDH1A1 (0.39) | ALDH1A1MAPK14MEN1KMT2ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20210355130-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2021-11-18 | — | — | US | disclosed |
| US-11161852-B1 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2021-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355130-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | ALDH1A1 4354/4885MAPK14 454/4885MEN1 1766/4885 |
| US-11713321-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | ALDH1A1 4354/4885MAPK14 454/4885MEN1 1766/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | ALDH1A1 4542/4885MAPK14 717/4885MEN1 3098/4885 |
| US-11161852-B1 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | ALDH1A1 4354/4885MAPK14 454/4885MEN1 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.